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Abstract 
 
Previously, we  reported  a Ca2+/calmodulin  (CaM)­dependent  impairment  of  apoptosis 
induced  by  serum  deprivation  in Alzheimer’s  disease  (AD)  lymphoblasts.  These  cell 
lines showed downregulation of ERK1/2 activity and elevated content of p21 compared 
to  control  cells.  The aim of this study was to delineate the molecular mechanism 
underlying the distinct regulation of p21 content in AD cells. Quantitative RT-PCR 
analysis demonstrated increased p21 mRNA levels in AD cells. The ERK1/2 inhibitor, 
PD98059, prevented death of control cells and enhanced p21 mRNA and protein levels. 
The CaM antagonist, CMZ, and the CaMKII inhibitor, KN-62, normalized the survival 
pattern of AD lymphoblasts by augmenting ERK1/2 activation and reducing p21 
mRNA and protein levels. Upregulation of p21 transcription in AD cells appears to be 
the consequence of increased activity of FOXO3a as the result of diminished ERK1/2-
mediated phosphorylation of this transcription factor, which in turn facilitates its 
nuclear accumulation. MDM2  protein  levels  were  decreased  in  AD  cells  relative  to 
control lymphoblasts, suggesting an impairment of FOXO3a degradation. 
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1. Introduction 
 
Alzheimer’s disease (AD) is a late-onset human neurodegenerative disorder marked by 
a progressive dementia and a spectrum of behavioral alterations. Whereas the hallmarks 
of AD, neurofibrillary tangles and amyloid- containing plaques are well established, 
the cause of neuronal loss remains largely elusive. Cumulative evidence has associated 
the aberrant re-expression of some cell cycle regulatory proteins with neuron 
vulnerability and neurodegeneration in AD (McShea, et al., 2007, Webber, et al., 2005). 
Cell cycle re-entry appears to represent an early and critical event in AD, leading to the 
development of AD-related pathology such as hyperphosphorylation of tau and 
amyloid- deposition and ultimately inducing neuronal cell death (Bonda, et al., 2010, 
Lee, et al., 2009). It is believed that certain neurons are able to reactivate cell-cycle 
activity in response to different triggers of neuronal apoptosis, including the withdrawal 
of growth factors (Park, et al., 1998) and other detrimental factors (Kruman, et al., 2002, 
Verdaguer, et al., 2002, Zhu, et al., 2007). Abnormal cell cycle re-entry leads to 
neuronal dead, however, in AD, the activation of neuronal cell cycle may result in 
apoptosis avoidance (Jellinger, 2006, Raina, et al., 2000), allowing the cells to arrest in 
G2, accumulating oxidative damage which in turn would induce its death according to 
the two-hit hypothesis (Moh, et al., 2011, Zhu, et al., 2004). 
Cell cycle dysregulation is not restricted to neurons, since peripheral cells from AD 
patients such as lymphocytes or fibroblasts have been shown to display cell cycle-
related alterations (Bialopiotrowicz, et al., 2011, de las Cuevas, et al., 2003, Nagy, et al., 
2002, Stieler, et al., 2012, Tatebayashi, et al., 1995, Zhang, et al., 2003). It appears 
therefore that cell cycle disturbances represent a systemic aspect of the disease.  While 
very limited data exist on the contribution of aberrant cell cycle in lymphocytes to the 
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clinical phenotype of AD, there is no doubt that peripheral cells from patients provide 
convenient material to study cell cycle-related events associated with neurodegeneration. 
Previous work from this laboratory indicated that immortalized lymphocytes from AD 
subjects show enhanced proliferative activity (de las Cuevas, et al., 2003, Muñoz, et al., 
2008) and more resistance to serum withdrawal-induced apoptosis in a Ca2+/CaM-
dependent manner (Bartolome, et al., 2007, de las Cuevas, et al., 2005). It was also 
shown that both CaM content and activity were enhanced in AD lymphoblasts (Esteras, 
et al., 2012). Two cell cycle regulatory proteins, the CDK inhibitors p27Kip1 and p21Cip1, 
from now on p27 and p21, are ultimately responsible for the enhanced proliferation and 
increased resistance to cell death, respectively. Whereas downregulation of p27 induces 
the enhanced proliferative response of immortalized lymphocytes from AD patients 
(Muñoz, et al., 2008), upregulation of p21 seems to help AD cells to escape from serum 
deprivation-induced apoptosis (Bartolome, et al., 2010). 
A number of recent studies pointed out that in addition to being an inhibitor of cell 
proliferation, p21 may protect cells from apoptosis (Gartel, 2009). For example, it has 
been reported that upregulation of p21 blocked the oxidative stress-induced death of 
human myeloma U266 cells (Kim, et al., 2001) and rendered resistance to 
chemotherapy drugs in other types of cancer cells (Gareau, et al., 2011). Thus the 
increase in p21 cellular content in AD lymphoblasts may confer these cells a survival 
advantage. 
This work was undertaken to unravel the molecular mechanisms underlying the 
Ca2+/CaM-mediated resistance of AD lymphoblasts to cell death induced by serum 
deprivation and the role of Ca2+/CaM in the regulation of p21 cellular levels. We tested 
the hypothesis that enhanced Ca2+/CaM signaling would protect AD cells from 
apoptosis via upregulation of p21. Our data suggest that CaMKII indirectly regulates the 
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FOXO3a-mediated activation of p21 transcription by preventing its phosphorylation 
mediated by ERK1/2 and subsequent translocation and degradation of this transcription 
factor via an MDM2-mediated ubiquitin-proteasome pathway. 
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2. Methods 
2.1. Materials. 
All components for cell culture were obtained from Invitrogen (Carlsbad, CA). 
Calmidazolium (CMZ), KN-62, pifithrin- (PFT-) and serum replacement were 
obtained from Sigma Aldrich (Alcobendas, Spain). LY294002 and PD98059 were 
obtained from Calbiochem (Darmstadt, Germany). PVDF (polyvinylidene difluoride) 
membranes for Western blots were purchased from Bio-Rad (Richmond, CA). Rabbit 
anti-human polyclonal antibodies, such as FOXO3a, ERK1/2, CaMKII, p53 and 
phospho-p53 (Ser 15) and rabbit anti-human monoclonal antibodies such as p21 and 
phospho-ERK1/2 were from Cell Signaling. Rabbit anti-human phospho-CaMKII 
(Thr286) (sc-12886-R), and mouse anti-human -tubulin (sc-23948) were from Santa 
Cruz Biotechnologies (Santa Cruz, CA). Rabbit anti-human -actin antibody was from 
Sigma. Rabbit anti-human MDM2 was from Millipore (Darmstadt, Germany). Mouse 
anti-human Lamin B was from Calbiochem. The enhanced chemiluminiscence (ECL) 
system was from Amersham (Uppsala, Sweden).  All other reagents were of molecular 
grade.  
2.2. Cell lines 
A total of 34 patients diagnosed in the department of Neurology of the University 
Hospital Doce de Octubre (Madrid, Spain) of probable Alzheimer according to 
NINCDS-ADRDA (National Institute of Neurological and Communicative Diseases 
and Stroke-Alzheimer’s Disease and Related Disorders Association) criteria were used 
in this study. Of the 34 patients, 20 had mild AD (DSM-III-R, Mini Mental State 
Examination (MMSE) score between 18-24), 7 had moderate AD (MMSE: 10-18), and 
7 had severe AD (MMSE: <10). A group of 23 non-demented age-matched individuals 
was used as control. In all cases peripheral blood samples were obtained after written 
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informed consent of the patients or their relatives. A summary of demographic 
characteristics of all subjects enrolled in this study is reported in Table 1. 
Establishment of lymphoblastic cell lines was performed in our laboratory as previously 
described by infecting peripheral blood lymphocytes with the Epstein-Barr virus 
(Koistinen, 1987). Cells were grown in suspension in T flasks in an upright position, in 
approximately 8 mL of RPMI-1640 (Gibco, BRL) medium that contained 2 mM L-
glutamine, 100 g/mL penicillin/streptomycin and, unless otherwise stated, 10 % (v/v) 
fetal bovine serum (FBS) and maintained in a humidified 5% CO2 incubator at 37 ºC. 
Fluid was routinely changed every two days by removing the medium above the settled 
cells and replacing it with an equal volume of fresh medium.  
2.3. Cell survival assay. 
The cell suspension was mixed with a 0.4% (w/v) Trypan Blue solution (Sigma), and 
the number of live cells was determined using a hemocytometer. Cells failing to exclude 
the dye were considered nonviable. In addition, apoptosis was characterized by 
chromatin condensation/fragmentation, as determined by cell fixation followed by 
DAPI staining and fluorescence microscopy examination.  
2.4 Determination of cell proliferation 
Cell proliferation was assessed by the 5-bromo-2’-deoxyuridine (BrdU) incorporation 
method, using an enzyme-linked immunoassay kit procured from Roche (Madrid, 
Spain). Cells (100,000 cells/well) were seeded in 96-well microtiter plates. Four hours 
prior to the end of the interval of measurement, BrdU  (10 μM) was  added. The cells 
were fixed with precooled 70% ethanol for 30 min at -20 ºC and incubated with 
nucleases  following manufacturer’s  recommendations.  Cells  were  then  treated  for  30 
min at 37 ºC with peroxidase-conjugated anti-BrdU antibody. The excess of antibody 
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was removed by washing the cells three times, followed by the addition of substrate 
solution. Absorbance was measured at 405 nm with a reference wavelength of 490 nm. 
2.5. Preparation of whole-cell extracts and subcellular fractionation.  
To prepare whole-cell extracts, cells were harvested, washed in PBS and then lysed in 
ice-cold buffer (50 mM Tris pH 7.4, 150 mM NaCl, 50 mM NaF, 1% Nonidet P-40), 
containing 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM sodium pyrophosphate 
and protease inhibitor Complete Mini Mixture (Roche, Mannhein).  
To separate the cytosolic and nuclear fractions, cells were harvested, washed in PBS 
and then lysed in ice-cold hypotonic buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 
mM ethylendiaminetetraacetic acid (EDTA), 0.1 mM ethylene glycol tetraacetic acid 
(EGTA), 1 mM sodium orthovanadate, 1 mM sodium pyrophosphate, 1 mM PMSF and 
protease inhibitor mixture. After extraction on ice for 15 min, 0.5% Nonidet P-40 was 
added and the lysed cells were centrifuged at 4000 rpm for 10 min. Supernatants 
containing cytosolic proteins were separated, and nuclei were washed twice with the 
hypotonic buffer, and then lysed in hypertonic buffer (20 mM HEPES, pH 7.9, 0.4 M 
NaCl, 1 mM ethylendiaminetetraacetic acid (EDTA), 1 mM ethylene glycol tetraacetic 
acid (EGTA), 1 mM sodium orthovanadate, 1 mM sodium pyrophosphate, 1 mM PMSF 
and protease inhibitor mixture. After extraction on ice for 30 min, the samples were 
centrifuged at 15000 rpm for 15 min at 4 ºC. Antibodies  to α-tubulin and to lamin B 
were used to assess the purity of the fractions. 
The protein content of the extracts was determined by the Pierce BCA Protein Assay kit 
(Thermo Scientific, Rockford, IL, USA). 
2.6. Western Blot Analyses 
50-100 g of protein from cell extracts were fractionated on a SDS polyacrylamide gel, 
and transferred to a PVDF membrane which was then blocked with 1-5% bovine serum 
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albumin (BSA) or 5% nonfat milk, and incubated overnight at 4ºC, with primary 
antibodies at the following dilutions: 1:1000 anti-p21, 1:1000 anti-FOXO3a, 1:2000 
anti-phospho ERK1/2, 1:1000 anti-ERK1/2, 1:500 anti-pCaMKII, 1:1000 anti-CaMKII, 
1:5000 anti--actin, 1:1000 anti--tubulin, 1:1000 anti-Lamin B, 1:1000 anti-phospho 
p53 (Ser 15), 1:1000 anti-p53 and 1:1000 anti-MDM2. Signals from the primary 
antibodies were amplified using species-specific antisera conjugated with horseradish 
peroxidase (Bio-Rad) and detected with a chemiluminiscent substrate detection system 
ECL (Amersham). The specificity of the antibodies used in this work was checked by 
omitting the primary antibodies in the incubation medium. Protein band densities were 
quantified using Image J software (NIH, Bethesda, Maryland, USA) after scanning the 
images with a GS-800 densitometer from BioRad. 
2.7. Quantitative Real-T ime PC R .  
Total RNA was extracted from cell cultures using Trizol reagent (Invitrogen). RNA 
yields were quantified spectrophotometrically and RNA quality was checked by the 
A260/A280 ratio and on a 1.2% agarose gel to observe the integrity of 18S and 28S 
rRNA. RNA was then treated with DNase I Amplification Grade (Invitrogen). One 
microgram was reverse transcribed with the Superscript III Reverse Transcriptase kit 
(Invitrogen). Quantitative real-time PCR was performed in triplicates using TaqMan 
Universal PCR MasterMix No Amperase UNG (Applied Biosystems) reagent according 
to the manufacturer’s protocol. Primers were designed using the Universal ProbeLibrary 
for Human (Roche Applied Science) and used at a final concentration of 20 M. The 
sequences  of  the  forward  and  reverse  primers  used  are  the  following:  for  p21  5’-
cgaagtcagttccttgtggag-3’  and  5’-catgggttctgacggacat-3’;  for  -actin  5’-
ccaaccgcgagaagatga-3’ and 5’-ccagaggcgtacagggatag-3’. 
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Real time quantitative PCR was performed in the BioRad iQ5 system using a thermal 
profile of an initial 5-min melting step at 95 ºC followed by 40 cycles at 95 ºC for 10 s 
and 60 ºC for 60 s. 
Relative mRNA levels of the genes of interest were normalized to -actin expression 
using the simplified comparative threshold cycle delta CT method [2 -(∆CT p21- ∆CT Actin].  
2.8. Confocal laser scanning microscopy 
 
Immortalized lymphocytes from control and AD individuals were seeded at an initial 
density of 1 x 106 cells x mL-1 and incubated in serum-free RPMI medium for 24 hours. 
Cells were fixed for 15 minutes in 4% paraformaldehyde in PBS and blocked and 
permeabilized with 0.5% Triton X-100 in PBS-0.5% BSA for 20 minutes at room 
temperature. Then, cells were incubated with rabbit anti-p21 monoclonal antibody (Cell 
Signaling). After washing with PBS, cells were incubated with Alexa Fluor 488-
conjugated anti-rabbit antibody. For nuclear staining, samples were incubated with 
DAPI (Sigma) at 4 mg/mL in PBS for 15 minutes at room temperature. The 
preparations were mounted on FluorSaveTM Reagent (Calbiochem, Madrid, Spain) and 
visualized with the Leica TCS-SP2-AOBS confocal microscope system (Heidelberg, 
Germany). 
2.9. Statistics 
Statistical analyses were performed on GraphPad Prism 5 for Macintosh (La Jolla, CA, 
USA). All the statistical data are presented as mean ± standard error of the mean (SEM). 
Statistical significance was calculated using an unpaired, two-tailed Student’s  t-test or, 
when appropriated, by analysis of variance (ANOVA)  followed by Bonferroni’s post-
hoc testing. A value of p<0.05 was considered significant. 
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3. Results 
 
3.1. CaM and E R K1/2 control of cell survival and p21 content. 
Data in Fig. 1 confirm and extend our previous findings that lymphoblasts from AD 
patients show increased resistance to cell death induced by serum deprivation in a 
Ca2+/CaM and ERK1/2 activity dependent manner (Bartolome, et al., 2007, Bartolome, 
et al., 2010). The  cell  response  to  serum deprivation was  not  dependent  on  disease’s 
severity, the average percentage of cell survival after 72 h of serum deprivation was 
98±2, 97±3 and 95±4 in lymphoblasts from mild (DSM-III-R, Mini Mental State 
Examination (MMSE) score between 18-24), moderate (MMSE: 10-18) or severe 
(MMSE: <10) AD patients, respectively. Further experiments were carried out with cell 
lines randomly selected among control individuals and the three groups of AD patients. 
The CaM antagonist, calmidazolium (CMZ) as well as the CaMKII inhibitor KN-62, 
rescued the normal cell response to serum deprivation, inducing apoptosis in AD cells, 
suggesting the involvement of CaMKII in the regulation of cell survival. The fact that 
these  drugs  didn’t  affect  the  survival  of  control  cells  suggests  a  threshold  for  CaM 
content/activity as the survival signal. On the other hand, the inhibitor of ERK1/2, 
PD98059, prevented the serum deprivation-induced apoptosis in control cells without 
significantly changing survival of AD lymphoblasts (Fig. 1B). To examine the apoptotic 
status of control and AD lymphoblasts after serum deprivation, cells were observed in a 
fluorescence microscopy following DAPI staining, which specifically binds to DNA. As 
shown in Fig. 1, the addition of CMZ or KN-62 to AD lymphoblasts induced chromatin 
condensation in some nuclei while PD98059 prevented the serum deprivation-induced 
apoptosis in control cells (Fig. 1C).  Taken together, these observations suggest a 
crosstalk between CaMKII and ERK1/2 in regulating the cellular response to serum 
deprivation. An inverse relationship was found between CaMKII and ERK1/2 activities, 
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as well as between ERK1/2 phosphorylation status and p21 levels in human 
lymphoblasts. As shown in Fig. 1D, AD lymphoblasts displayed higher activity of 
CaMKII, as monitored by the enhanced autophosphorylation, together with decreased 
ERK1/2 activity, when compared with control cells.  In parallel, levels of p21 increased 
in agreement with previous reports (Bartolome, et al., 2010). Moreover, as it was the 
case for changes in other cell cycle-related events reported in AD lymphoblasts 
(Bartolome, et al., 2009), we did not observe significant differences in p21 content 
among mild, moderate or severe AD patients (results not shown). Inhibition of CaMKII 
with CMZ treatment in AD cells restored the activity of ERK1/2 and diminished the 
p21 cellular content up to the levels observed in control cells. Under these conditions, 
AD cells underwent apoptosis as control cells did. Thus, it appears that 
CaM/CAMKII/ERK1/2 signaling pathway controls cell survival under trophic factor 
deprivation by regulating p21 levels. 
To rule out that differences in p21 content could induce changes in the proliferative 
activity that could mask the distinct survival response of AD lymphoblasts, we carried 
out a comparative analysis of BrdU incorporation into DNA in control and AD cells 
after the treatment with the CaMKII or ERK1/2 inhibitors. As shown in Table 2, no 
differences were found in cell proliferation between control and AD lymphoblasts in the 
absence or in the presence of these inhibitors. Thus, under serum deprivation, the 
increased p21 content has a predominant anti-apoptotic role. 
3.2. Regulation of p21 levels 
To elucidate the molecular basis for the upregulation of p21 in AD lymphoblasts, we 
tested whether this effect was dependent on altered protein degradation. To this end, we 
evaluated the stability of the p21 protein after serum-deprivation, by treating control and 
AD cells with 20 g/mL of cycloheximide to inhibit de novo protein synthesis. At the 
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indicated time, steady-state levels of p21 protein were determined by immunoblotting 
(Fig. 2). As in other cell types, p21 is a short-lived protein in human lymphoblasts.  
Inhibition of protein synthesis with cycloheximide led to a rapid decrease in p21 levels, 
with less than 50% remaining after 2 hours. It is shown that p21 half-life is identical in 
both control and AD lymphoblasts. We next determined, by quantitative RT-PCR, p21 
mRNA levels. As shown in Fig. 3, lymphoblasts from AD patients show an increase in 
expression of p21 mRNA as compared with control cells, in consonance with the 
different content of this protein in control and AD lymphoblasts. Inhibition of CaMKII 
by CMZ or KN-62 abrogated the increased transcription of p21 in AD cells, while 
inhibiting the PI3K/Akt pathway by Ly294002 had no consequences in p21 mRNA 
levels (Fig. 3). On the contrary, the ERK1/2 inhibitor PD98059 was able to increase p21 
mRNA levels in control cells without affecting the transcription of the gene in AD 
lymphoblasts. Under these conditions, and in agreement with previous reports 
(Bartolome, et al., 2010), control cells were found to be resistant to cell death induced 
by serum deprivation (Fig. 1C).  Taken together, these results suggest that CaMKII 
regulates p21 mRNA expression levels by downregulating the activity of ERK1/2.  
3.3. Regulation of p21 transcription 
Transcriptional activation of p21 gene is regulated though p53-dependent and -
independent mechanisms. We first tested whether the transcriptional activation of the 
p21 gene was dependent on p53 activity. For this purpose, we analyzed by Western Blot 
phospho-p53 at Ser 15 together with total p53 and p21 levels in the absence and in the 
presence of the p53 inhibitor pifithrin-α (PFT-α) (Zhu, et al., 2002b), and analyzed the 
influence of this inhibitor on cell survival after 72 h of serum withdrawal. Neither total 
nor phosphorylated (active form (Siliciano, et al., 1997)) p53 levels changed in AD 
lymphoblasts when compared with control cells despite the increased content of p21 in 
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AD cells (Fig. 4A). Treatment with PFT-α effectively decreased the levels of phospho-
p53 and total p53, but had little effect on p21 levels (Fig. 4A) and didn’t overcome the 
resistance of AD cells to death induced by serum withdrawal (Fig. 4B). 
We next focused on p53-independent mechanisms of p21 transcriptional activation. The 
transcription factor FOXO3a has been shown to mediate the transcriptional 
transactivation of p21 gene in some type of cells (Hauck, et al., 2007), and it has also 
been reported that sustained ERK activation results in FOXO3a downregulation (Yang, 
et al., 2008). Levels of FOXO3a were first determined in control and AD lymphoblasts. 
As observed in Fig. 5A, AD cells show a higher content of FOXO3a than control cells. 
FOXO3a is known to be phosphorylated at Ser 294, Ser 344 and Ser 425 by ERK1/2 
(Yang, et al., 2008). Phosphorylation of the molecule is required for the export of the 
transcription factor from the nucleus to be degraded (Obsil and Obsilova, 2008). We 
could not find a suitable phospho-specific antibody to recognize phosphorylated 
FOXO3a at these residues, to assess possible differences in phosphorylation status of 
FOXO3a between control and AD lymphoblasts as the result of their intrinsic 
differences in ERK1/2 activity (see Fig.1D). Thus, to address this issue, we performed 
subcellular fractionation experiments to determine whether there is a distinct 
distribution of FOXO3a in AD cells. We found a preferentially nuclear localization of 
FOXO3a in the nucleus, which is significantly enhanced in AD lymphoblasts (Fig. 5B). 
We did not detect significant changes in the cytosolic content between control and AD 
cells (Fig. 5), most likely due to possible differences in the rate of cytosolic degradation 
of this transcription factor in control or AD lymphoblasts. We then aimed at elucidating 
whether inhibiting ERK1/2 activation by PD98059 or alternatively increasing ERK1/2 
phosphorylation with the CaM antagonist CMZ or the CaMKII inhibitor KN-62 impacts 
the nuclear accumulation of FOXO3a. First of all, Fig. 6A shows the efficacy of these 
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drugs modulating the activity of ERK1/2. Then, subcellular fractionation was performed 
to assess the nuclear content of FOXO3a under the different experimental conditions. 
Fig. 6B shows that PD98059 treatment effectively increased the nuclear levels of 
FOXO3a in control cells, while increasing the activation of ERK1/2 by inhibiting 
CaMKII by CMZ or KN-62 abrogated the enhanced nuclear levels of AD cells to levels 
similar to those of control cells (Fig. 6C).  
After being exported from the nucleus, phosphorylated FOXO3a is then degraded in the 
cytosol via an MDM2-mediated ubiquitin-proteasome pathway (Yang, et al., 2008). 
Moreover, ERK1/2 has been shown to upregulate MDM2 protein expression levels 
(Phelps, et al., 2005, Ries, et al., 2000). On these grounds, we were interested at 
elucidating whether control and AD lymphoblasts display distinct MDM2 levels. As 
shown in Fig. 7, we observed higher levels of MDM2 and ERK1/2 activation in control 
lymphoblasts when compared with lymphoblasts from AD patients. On the other hand, 
the inhibition of ERK1/2 activity decreased significantly the cellular content of MDM2 
protein (Fig. 7). Thus, it seems that MDM2 may function as the ubiquitin ligase for 
FOXO3a proteasome degradation in human lymphoblasts. Taken together the results 
suggest that downregulation of ERK1/2-mediated phosphorylation of FOXO3a in AD 
lymphoblasts may compromise its transport from the nucleus and its interaction with 
MDM2, to reduce the degradation of the molecule. The non-phosphorylated FOXO3a 
accumulated in more extent in the nucleus of AD lymphoblasts, thereby promoting the 
enhanced transcription of p21. 
3.4. Intracellular localization of p21. 
The p21 protein has been considered as a paradigm of protein showing completely 
different nuclear and cytosolic functions (Agell, et al., 2006, Coqueret, 2003). Therefore, 
we decided to examine whether there are differences in the subcellular localization of 
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p21 in control and AD lymphoblasts. For this purpose, we performed nuclear and 
cytoplasmic fractionation and analyzed the protein extracts by Western Blot. As shown 
in Fig. 8, p21 is accumulated in the cytoplasm rather than in nucleus, both in control 
and AD cells. Nuclear and cytoplasmic content of p21 are higher in AD lymphoblasts in 
consonance with the increased mRNA p21 levels. Similar results were obtained when 
cells were immunostained and processed for confocal laser imaging, as shown in Fig. 8. 
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4. Discusion 
In AD lymphoblasts, the constitutive activation of Ca2+/CaM-dependent signaling 
pathways enhances cell proliferation and survival. Among them, the PI3K/Akt and 
ERK1/2 seem to play important roles in controlling cell fate depending on growth factor 
availability (de las Cuevas, et al., 2010). These tumor-like features of lymphoblasts 
from AD patients were considered as systemic manifestations of the proposed 
relationship between cellular stress and unscheduled cell cycle entry observed in 
susceptible neurons in AD (Zhu, et al., 2004). While the CaM-dependent overactivation 
of PI3K/Akt regulates cell proliferation by enhancing the rate of p27 degradation 
(Muñoz, et al., 2008), here we report that ERK1/2 activation following serum 
deprivation is negatively regulated by CaMKII in AD cells, leading to an increase in 
FOXO3a activity, thereby enhancing the transcription of p21 and the survival of 
lymphoblasts from AD patients. Several lines of evidence support this assumption; first, 
CaMKII and ERK1/2 activation are inversely correlated in immortalized lymphocytes, 
CaMKII activity is increased in AD cells together with decreased ERK1/2 
phosphorylation in the absence of serum; second, CaMKII inhibition restored ERK1/2 
phosphorylation and decreased the levels of p21 in AD cells, thus sensitizing AD cells 
to apoptosis; and third, inhibition of ERK1/2 by PD98059 prevented the serum 
deprivation-induced death in control cells by increasing the cellular content of FOXO3a 
and the levels of p21. 
FOXO3a is a member of the class O subgroup of the forkhead transcription factor 
family, which is expressed in many different tissues and involved in mediating the 
effects of growth factors on several cellular processes including cell cycle progression, 
glucose metabolism, and apoptosis (Accili and Arden, 2004, Greer and Brunet, 2008, 
Kops, et al., 2002). The activity of FOXO3a as a transcriptional regulator is primarily, 
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although not exclusively, controlled by its subcellular localization (Vogt, et al., 2005). 
In the absence of growth or neurotrophic factors, FOXO3a may localize to the cell 
nucleus, causing transcriptional induction of a variety of genes (Modur, et al., 2002). 
Our results indicate that the cellular content of FOXO3a is enhanced in serum-deprived 
AD lymphoblasts. Under these conditions, FOXO3a accumulated mainly in the nucleus, 
inducing the transcription of p21 and favoring the cell resistance to serum deprivation. 
FOXO3a levels appear to be controlled by CaM/CaMKII/ERK1/2-mediated 
phosphorylation, and subsequent degradation of the molecule in the cytosolic 
compartment by an MDM2-mediated ubiquitin-proteasome pathway as suggested by the 
observed decrease in the cellular content of MDM2 protein in AD lymphoblasts.   
Experimental evidence supports the idea that important oncogenic kinases such as 
PI3K/AKT, IKK and ERK1/2 are involved in regulating FOXO3a nuclear localization 
and activity through phosphorylation at different sites (Hu, et al., 2004, Plas and 
Thompson, 2003, Yang, et al., 2008). However, in human lymphoblasts, inhibition of 
PI3K/Akt has no consequences in the transcription of p21 (this manuscript) or in p21 
levels and cell survival (Bartolome, et al., 2010). Our data indicate that inhibiting 
ERK1/2 activity by PD98059 might prevent phosphorylation of FOXO3a, allowing the 
nuclear accumulation of FOXO3a, increasing its transcriptional activity and blocking 
the serum withdrawal-induced death in control lymphoblasts. 
In addition to the increased transcriptional activation of p21 gene observed in AD 
lymphoblasts, we also found an increase in the cytosolic content of p21 of AD cells. 
The cytoplasmic p21 is thought to be a positive modulator of cell survival 
(Blagosklonny, 2002, Coqueret, 2003).  
On the other hand, we did not observe changes in the rate of p21 degradation following 
serum deprivation. This observation is in contrast with the previously reported increase 
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in p21 degradation in AD lymphoblasts under proliferating conditions (Sala, et al., 
2008). Thus, it seems that serum stimulation or withdrawal induced opposite changes in 
p21 cellular content by affecting protein stability or transcription respectively.  
The increased levels of p21 in AD lymphoblasts associated with enhanced resistance to 
death induced by serum deprivation reported here, are in line with the observation that 
upregulation of p21 blocked the oxidative stress-induced death of human myeloma 
U266 cells (Kim, et al., 2001) and rendered resistance to chemotherapy drugs in other 
types of cancer cells (Gareau, et al., 2011). Thus the increase in p21 cellular content in 
AD lymphoblasts may confer these cells a survival advantage similar to that described 
for cancer cells (Weiss, 2003).  Increased levels of p21 may protect cells from apoptosis 
through different mechanisms: p21 can interact and inhibit the activity of caspases 
(Roninson, 2002), it can also bind to E2F1 and MYC preventing their transcriptional 
induction of pro-apoptotic proteins (Abbas and Dutta, 2009). On the other hand, p21 
can mediate the upregulation of anti-apoptotic proteins (Dotto, 2000). Interestingly, 
upregulation of p21 has also been associated with blockade of oxidative stress-induced 
apoptosis in fibroblasts from AD patients (Naderi, et al., 2006). In this sense, it is worth 
to note that a selective impairment of mechanisms involved in cell death has been 
previously reported in peripheral cells from AD patients (Eckert, et al., 2001, Morocz, 
et al., 2002, Naderi, et al., 2006, Uberti, et al., 2002) although there are conflicting 
results as to whether cells from AD patients are more resistant or more vulnerable to 
situations that promote cell death. Most likely these discrepancies result from the 
different cell types and stress-inducing conditions used. 
AD cells treated with the CaM antagonist CMZ or the CaMKII inhibitor KN-62 
undergo significant apoptosis in the absence of serum in the culture medium as they do 
control cells. The effects of these compounds are accompanied by activation of ERK1/2 
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together with decreased levels of FOXO3a and p21. Inactivation of CaMKII has no 
effects in control cells suggesting a threshold for CaM activation as the survival signal. 
Our results are in consonance with previous reports indicating that CaM antagonists 
specifically resulted in apoptosis in tumorigenic mammary carcinoma cells, but did not 
affect normal mammary gland-derived epithelial cells (Deb, et al., 2004). 
CaM/CaMKII downregulates ERK1/2 activity in human lymphoblasts by a mechanism 
not yet completely defined. Several mechanisms for CaM/CaMKII modulation of 
ERK1/2 have been proposed. For example, it was shown in thyroid cancer cells that 
CaMKII associates and phosphorylates Raf-1, contributing to ERK activation (Illario, et 
al., 2003). On the other hand, it was reported that CaM negatively regulates the 
Ras/Raf/MEK/ERK pathway in fibroblasts (Villalonga, et al., 2001). CaMKII can 
activate in vitro synGAP (Oh, et al., 2004), a Ras inhibitory GTPase expressed in 
neurons (Kim, et al., 1998), which may inhibit ERK activation. Recently, it has been 
shown that CaM may prevent the phosphorylation of K-Ras by different kinases and 
that inactivation of CaM leads to K-Ras activation (Alvarez-Moya, et al., 2011). 
Apparently, both the C-terminal polylysine region and the farnesylation of K-Ras are 
important for its specific interaction with CaM (Wu, et al., 2011). Whether there are 
similar mechanisms operative in human lymphocytes and impaired in AD patients will 
need further investigation. 
In addition to the indirect effect of CaM/CaMKII on cellular content of FOXO3a levels, 
by preventing its phosphorylation by ERK1/2, and favoring thereafter the transcription 
of p21, one must consider the possibility that these genes belong to the recently 
described gene pool, apparently important for adaptive processes, whose expression is 
highly sensitive to nuclear Ca2+/CaM signaling (Zhang, et al., 2009). 
Impaired CaMKII activation has also been detected in AD brain, associated with 
  21 
increased phosphorylation of tau and neurofibrillary tangle formation (McKee, et al., 
1990). Similarly, abnormal ERK1/2 activation has been found in degenerating neurons 
(Zhu, et al., 2002a). ERK1/2 pathway appears to be actively involved in the 
pathogenesis of AD, by altering hippocampal synaptic plasticity, and contributing to 
memory deficit (Derkinderen, et al., 1999). On the other hand, increased FOXO3a 
activity has been found in the brain of the Tg2576 mouse model of AD compared with 
wild-type mice (Qin, et al., 2008) correlating with increased A1-40 and A1-42 
peptide contents. It is also worth mentioning that overexpressed p21 has also been 
detected in the frontal cortex of AD brains (Engidawork, et al., 2001).  Thus, our results 
obtained in peripheral cells from AD patients demonstrate that dysfunction of 
CaMKII/ERK1/2/FOXO3a signaling is not restricted to the brain, but rather represents a 
systemic aspect of the disease. These findings also suggest that changes in B-
lymphocytes may contribute to the AD-specific phenotype, in agreement with previous 
reports highlighting the role of alterations in cells of the immune system in AD 
pathogenesis (Prinz, et al., 2011). While most of the studies on AD lymphocytes have 
been focused in detecting disease-specific changes that may serve as biomarkers, it 
remains to be established the clinical consequences, if any, of the altered response of 
lymphocytes in AD patients.  
 In summary, we have provided evidence that in the absence of serum, the survival of 
AD lymphoblasts depends on the CaMKII-induced downregulation of ERK1/2 activity, 
leading to increased accumulation of FOXO3a in the nucleus, and therefore to enhanced 
transcription of p21. The proposed scenario is represented schematically in Fig. 9. Our 
data indicate that the direct inverse coupling of CaMKII and ERK1/2 and ERK and 
FOXO3a activity function as key switches in controlling cell fate survival or death 
depending on growth factors availability. Finally, increased resistance of cells to death 
  22 
induced by serum deprivation and elevated p21 levels appear to be early features in AD 
pathogenesis, since similar changes were observed in mild, moderate or severe AD 
patients. 
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Tables 
Table 1 
 Summary of study population 
 
 
Control, healthy control individuals, no sign of neurological disease; AD, patients with 
a diagnosis of probable AD.  
 Control 
n=23 
AD 
n=34 
Age 751 765 
Age range (60-83) (59-89) 
Gender 
Male 8 15 
Female 15 19 
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Table 2 
BrdU incorporation into DN A of human lymphoblasts 
Treatment 
Absorbance 405/490 nm 
Control AD 
None 0.111 ± 0.03 0.115 ± 0.01 
CMZ 1 M 0.114 ± 0.03 0.110 ± 0.005 
KN-62 1 µM 0.108 ± 0.04 0.102 ± 0.06 
PD98059 20 µM 0.124 ± 0.03 0.124 ± 0.02 
 
Immortalized lymphocytes from control and AD patients (105 cells/well) were seeded in 
96-well plates in RPMI medium containing 10% Serum Replacement (SR). After 24 h 
of serum deprivation, cells were pulsed with 10 µM BrdU for 4 h. DNA synthesis was 
assessed  by  BrdU  incorporation  method  according  to  manufacturer’s instructions. 
Values shown are the mean ± SEM of three different cell lines in each condition 
performed in triplicate. 
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Legends to the F igures 
F igure 1 
Survival of control and A D lymphoblasts in serum-deprived medium. Influence of 
CaM K I I and E R K1/2 on cell survival and p21 content. 
 
A . Scatter plot comparing cell survival following serum deprivation between 
lymphoblasts derived from control or Alzheimer’s disease (AD) patients. Immortalized 
lymphocytes from control (open symbols) and AD individuals (filled symbols) were 
seeded at an initial density of 1 x 106 cells x mL-1 and incubated in serum-free RPMI 
medium for 72 hours. Cell viability was determined by trypan blue exclusion under 
inverted phase-contrast microscopy. Statistical significance was determined by the 
Student’s  t-test. B. Percentage of surviving cells, measured as above, after treatment 
with  1  μM  calmidazolium  (CMZ),  1  μM  KN-62  or  20  μM  PD98059.  Experimental 
conditions are identical to those described in A. Data shown are the mean ± SEM of six 
different experiments carried out with different cell lines, and expressed as percentage 
of the initial number of cells at day 0. *p<0.05 significantly different from untreated 
control cells. +p<0.05 significantly different from untreated AD lymphoblasts. C . 
Representative photomicrograph of DAPI-stained lymphoblasts following 72 hours of 
serum deprivation in the absence or in the presence of 1 μM CMZ, 1 μM KN-62 or 20 
µM PD98059. Arrows show the presence of chromatin condensation/fragmentation 
indicating apoptosis. No signs of apoptosis were detected in cells treated with PD98059. 
Treatment of AD cells with CMZ or KN-62, sensitized AD lymphoblasts to death 
induced by serum deprivation. D. Effects of CMZ on CaMKII and ERK1/2 activities 
and p21 content in control and AD lymphoblasts. Representative immunoblots are 
shown. Densitometric analyses of phosphorylated CaMKII and p21 content represent 
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the mean ± SEM of four independent observations carried out with different cell lines. 
*p<0.05 significantly different from control cells. +p<0.05 significantly different from 
untreated AD lymphoblasts. 
 
F igure  2 
Half-life of p21 in control and A D lymphoblasts. 
Lymphoblasts from control and AD subjects were seeded at an initial density of 1 x 106 
cells x mL-1 and incubated in the presence of cycloheximide (20 μg/mL) in serum-free 
RPMI medium. Cells were harvested 1, 3, and 6 hours thereafter and p21 was detected 
by immunoblotting. Blots from a representative experiment are shown. The decay of the 
p21 signal was graphed as a function of time post-cycloheximide addition, using data 
from different experiments carried out with of cell lines derived from six control and six 
AD subjects.  
F igure 3 
Relative p21 mRN A abundance in control and A D lymphoblasts. 
Immortalized lymphoblasts from control and AD individuals were seeded at an initial 
density of 1 x 106 x mL-1 and cultured for 24 hours in serum-free RPMI medium as 
described in legend to Fig. 1 with 1 μM CMZ, 1 μM KN-62, 20μM PD98059 or 1μM 
Ly294002. Cells were then collected and subjected to quantitative RT-PCR. Relative 
mRNA levels of the p21 gene in the different experimental conditions were normalized 
to -actin expression, and values for control cells were set as one. Values shown are the 
mean ± SEM for seven different control or AD cell lines. *p<0.05, **p<0.01  
significantly different from control cells; +p<0.05, ++p<0.01 significantly different 
from untreated AD cells 
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F igure 4 
E ffects of pifithrin- (PF T-) on p53 and p21 content and in survival of control 
and A D lymphoblasts. 
Lymphoblasts from control and AD subjects were incubated in serum-free RPMI 
medium for 72 hours in the absence or in the presence of 30 µM PFT-α. A . To assess 
the effects of the drug on p21 and p53 content and in p53 phosphorylation in Ser 15, 
cell extracts for Western Blot were prepared at 24 hours. A representative immunoblot 
is shown. Densitometric analyses of p21, p-p53 (Ser 15) and total p53 content represent 
the mean ± SEM from different observations carried out with four different cell lines. 
*p<0.05 significantly different from untreated control cells, +p<0.05 significantly 
different from untreated AD cells. B . Cell viability was determined by trypan blue 
exclusion under inverted phase-contrast microscopy. Data shown represent the mean ± 
SEM from different observations carried out with five different cell lines.*p<0.05,  
**p<0.01 significantly different from untreated control cells.  
 
 
F igure 5 
Relative F O X O3a abundance and subcellular localization in control and A D cells 
A . Lymphoblasts from control and AD cells were seeded at an initial density of 1 x 106 
cells x mL-1 and serum-starved for 24 hours. At that time, cell extracts for Western 
Blotting were prepared. A representative immunoblot is shown. Densitometric analyses 
of FOXO3a content represent the mean ± SEM of different experiments performed with 
ten different control or AD subjets. *p<0.05 significantly different from control cells. B . 
Experiments were performed under the same conditions described in A. In this case, 
cells were fractionated into cytosolic and nuclear fractions and subjected to Western 
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Blot. Lamin B and -tubulin were used as control of purity and loading of nuclear and 
cytoplasmic protein extracts, respectively. Data represent the mean ± SEM of different 
experiments carried out with eight different cell lines derived from control or AD 
patients. *p<0.05, significantly different from control nucleus.   
F igure 6 
Influence of CaM K I I and E R K1/2 on F O X O3a nuclear localization 
A . Cells were seeded at an initial density of 1 x 106 cells x mL-1 and incubated in serum-
free RPMI medium in the absence or in the presence of 20 μM PD98059, 1 μM CMZ or 
1 μM KN-62 for 24 hours. Part of these cells was used to prepare whole-cell extracts, 
which were subjected to Western blot to check the effects of these drugs on ERK 
phosphorylation, as shown in a representative immunoblot. B . The rest of the cells were 
fractionated to get the nuclear fraction. Nuclear FOXO3a abundance as determined by 
Western Blot in the absence or in the presence of PD98059 was calculated with data 
derived from experiments using eight different cell lines. *p<0.05, significantly 
different from untreated control. C . Under the same conditions as B, nuclear FOXO3a 
abundance as determined by Western Blot was calculated in the absence or in the 
presence of CMZ and KN62. Representative immunoblots are shown. Four different 
cell lines derived from control or AD subjects were used to perform the experiments. 
*p<0.01, significantly different from untreated control; +p<0.05, significantly different 
from untreated AD; +p<0.01, significantly different from untreated AD. Densitometric 
analyses represent in all cases the mean ± SEM. 
 
 
 
  36 
F igure 7 
E ffects of E R K1/2 on M D M2 content in control and A D lymphoblasts. 
Cells were seeded at an initial density of 1 x 106 cells x mL-1 and incubated in serum-
free RPMI medium in the absence or in the presence of 20 μM PD98059 for 24 hours, 
when they were collected to prepare whole-cell extracts for Western Blot. A 
representative immunoblot is presented. Densitometric analyses of MDM2 content 
represent the mean ± SEM of different experiments carried out with six different cell 
lines from control or AD patients. *p<0.05 significantly different from untreated control. 
 
 
F igure 8 
Subcellular localization of p21 in control and A D lymphoblasts. 
A . Lymphoblasts from control and AD patients were seeded at an initial density of 1 x 
106 cells x mL-1, incubated in the absence of serum for 24 hours, and then fractionated 
to determine by immunoblot the subcellular localization of p21. Antibodies to -tubulin 
and to lamin B were used as control of purity and loading of cytoplasmic and nuclear 
protein extracts, respectively. A representative immunoblot is shown, whereas the 
densitometric analysis is presented below. Data represent mean ± SEM of eight 
experiments. *p<0.01 significantly different from cytosol of control cells. B . p21 
localization was also studied by confocal microscopy. Under the same conditions than 
A, cells were stained with anti-p21 antibody followed by secondary antibody labeled 
with Alexa Fluor 488. DAPI was used for nuclear staining. Merged images depict a 
predominant cytosolic localization for p21, more evident in AD cells. Magnification: 
63x. 
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F igure 9 
Diagram summarizing the role of CaM K I I/E R K1/2/F O X O3a pathway in 
regulating p21 content and survival of A D lymphoblasts. 
 
In control cells, serum withdrawal promotes ERK1/2 activation, which then presumably 
induces phosphorylation of FOXO3a and its posterior degradation in the cytosolic 
compartment in an MDM2-mediated manner. In AD cells, ERK1/2 activation is 
downregulated by the enhanced CaMKII activity. Reduced ERK1/2 activity partially 
prevents phosphorylation and degradation of FOXO3a increasing thereby the 
transcriptional activation of p21, which in turn protects cells from apoptosis.  
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